- Home
- Publications
- Publication Search
- Publication Details
Title
Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
Authors
Keywords
Multiple Sclerosis, Macular Edema, Expand Disability Status Scale, Progressive Multifocal Leukoencephalopathy, Natalizumab
Journal
CNS DRUGS
Volume 29, Issue 7, Pages 565-575
Publisher
Springer Nature
Online
2015-08-03
DOI
10.1007/s40263-015-0261-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis
- (2015) N. Pfender et al. NEUROLOGY
- Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
- (2015) Ann M. Arvin et al. JAMA Neurology
- Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
- (2014) John Camm et al. AMERICAN HEART JOURNAL
- Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab
- (2014) Assunta Bianco et al. EUROPEAN NEUROLOGY
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
- (2014) T. Olsson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator
- (2014) Andreas Krause et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Relapses in patients treated with fingolimod after previous exposure to natalizumab
- (2014) G Comi et al. Multiple Sclerosis Journal
- ACTRIMS-ECTRIMS MSBoston 2014: Late Breaking News Oral Presentations
- (2014) Multiple Sclerosis Journal
- Fingolimod after natalizumab and the risk of short-term relapse
- (2014) V. G. Jokubaitis et al. NEUROLOGY
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
- (2014) G. Karlsson et al. NEUROLOGY
- Switching From Natalizumab to Fingolimod in Multiple Sclerosis
- (2014) Mikael Cohen et al. JAMA Neurology
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
- (2013) Marco A. Zarbin et al. OPHTHALMOLOGY
- The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
- (2012) P Gergely et al. BRITISH JOURNAL OF PHARMACOLOGY
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
- (2011) Jeffrey A. Cohen et al. ANNALS OF NEUROLOGY
- Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
- (2011) A. Kerbrat et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
- (2011) M. Mehling et al. NEUROLOGY
- Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
- (2010) Augusto Miravalle et al. ARCHIVES OF NEUROLOGY
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started